Haiying Shen, M.D., Ph.D.
Senior Research Scientist
Phone: 503-413-2484 | Email: email@example.com
Dr. Haiying Shen received his M.D., training and Ph.D. degree in surgical science from the Third Medical University, and completed his post-doctoral fellowship training in neuropharmacology at the Department of Neurology, Boston University School of Medicine.
Dr. Shen has served as a Principal Investigator or Co-Investigator on grants from prominent national and local research foundations, he has authored over 40 peer-reviewed scientific publications and is a recognized expert in adenosine-based neurobehavioral research.
Sarcosine Suppresses Epileptogenesis in Rats With Effects on Hippocampal DNA Methylation.
Dysregulation of adenosine kinase isoforms in breast cancer.
Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia.
Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition.
A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs.
Dr. Shen’s research is considered translational to bridge between laboratory-based discovery and clinical drug development. Dr. Shen has expertise in the areas of adenosine-based neurobehavioral mechanisms of brain diseases, with a specific focus on the development of novel therapeutic strategies to modify the brain function against epilepsy and other neuropsychiatric disorders. The main projects in Dr. Shen’s lab focus on how to prevent the development of seizures and the progression of epilepsy, as well as prevent epilepsy-related comorbidities, including cognitive deficits, neurodegeneration, and sudden unexpected death in epilepsy (SUDEP).
Another research focus of Dr. Shen is to explore the role of adenosine regulation in malignant tumors, with a view to develop new pharmacological approaches for brain tumor treatment. A recent study from the Shen Lab using pharmacological and gene therapy approach revealed the role of the adenosine metabolic enzyme in modulating cancer growth.